Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

Phase 2 Completed 40 enrolled University of Michigan Rogel Cancer Center American Society of Clinical Oncology · collab

NaSingle-groupOpen-labelSupportive care

Summary

Study of Cannabidol to examine the safety and efficacy of 15 weeks of CBD in postmenopausal women with aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). Investigators are looking to see if patients with joint pain see improvement with the use of CBD.

Timeline

Start: 2021-04-16
Primary completion: 2023-10-10
Completion: 2023-10-10

Publications

Fleege NMG, Miller EA, Kidwell KM, Zacharias ZR, Houtman J, Scheu K, Kemmer K, Boehnke KF, Henry NL. Pilot Study of Cannabidiol for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Breast Cancer. Cancer Med. 2025 Aug;14(15):e71117. doi: 10.1002/cam4.71117.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cannabidiol	Other / unclassified	100 mg	Oral

Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

Summary

Timeline

Publications

Drugs

Indications